Summary: A recent study reveals a new biological pathway involved in Alzheimer’s disease and identifies a promising therapeutic candidate capable of slowing its progression. Researchers found that the cellular enzyme GRK2 becomes inactivated and aggregates in the brains of dementia patients, damaging mitochondria and triggering a self-reinforcing cycle that increases production of toxic amyloid-beta. The team developed a targeted molecule called “Compound 10” that prevents GRK2 aggregation, preserves mitochondrial function, and delays neuronal death in animal models.
The findings offer a new drug development target for Alzheimer’s: interrupting the GRK2 aggregation–mitochondrial dysfunction–amyloid-beta loop could reduce neuronal loss and extend survival in models of the disease.
Key Facts
- Two decades of tissue research: The investigation began nearly 20 years ago, using human brain tissue samples collected during tumor surgeries to compare brains from dementia patients with non-dementia controls.
- Target protein—GRK2: G protein-coupled receptor kinase 2 (GRK2) is a regulatory enzyme important for cellular stress responses in both brain and heart cells. The study links pathological changes in GRK2 to Alzheimer’s pathology.
- Inactivation and aggregation: Molecular analyses of human tissue and mouse models show that metabolic changes convert active GRK2 into an inactivated, phosphorylated form that clumps into aggregates.
- Mitochondrial pore blockade: Aggregated, inactive GRK2 deposits onto mitochondria, obstructing their pores, reducing cellular energy output, and producing intracellular stress that undermines neuronal survival.
- Amyloid-beta feedback loop: Inactive GRK2 accelerates amyloid-beta production, and the resulting amyloid-beta increases cellular stress that drives further GRK2 inactivation and aggregation—creating a self-perpetuating pathological cycle.
- Compound 10: Screening of small molecules identified Compound 10 as a potent inhibitor of GRK2 aggregation. In mice, treatment improved mitochondrial function, reduced amyloid-beta accumulation, and extended survival.
- Systemic benefits observed: Beyond brain protection, treated animals showed improved cardiac performance and systemic markers consistent with slowed aging, such as fewer grey hairs in later life.
- Longitudinal timeline: Because Alzheimer’s is age-related, the work required experiments in older mice (1.5–2 years), lengthening each experimental cycle and contributing to the extended timeline of the research.
Source: ETH Zurich
“Compound 10” is the name given by the research team to their lead compound that prevents harmful GRK2 aggregation and demonstrably slows neurodegenerative changes in preclinical models. The molecule was developed and tested primarily in cultured cells and aged mouse models, producing promising results for mitochondrial preservation and neuronal survival.
A new molecular point of attack
Professor Ursula Quitterer and colleagues focused on GRK2, an enzyme that helps brain and heart cells respond to stress and signaling. Detailed analyses of long‑stored human tissue samples and transgenic mouse models revealed that, in Alzheimer’s pathology, GRK2 shifts from its protective, monomeric form into a phosphorylated, inactive form that aggregates. These aggregates localize to neuronal mitochondria, impairing their function and compromising cellular energy supply.
The study, published in Cell Reports Medicine, connects GRK2 dysfunction directly to two Alzheimer’s hallmarks—amyloid-beta and tau pathology—and shows how these interactions can accelerate neurodegeneration.
How a protective enzyme becomes pathogenic
Cells normally contain both functional GRK2 and a metabolically inactivated variant. In dementia-affected brains and Alzheimer’s mouse models, the phosphorylated, inactive form (phospho‑S670‑GRK2) accumulates and forms aggregates. These aggregates attach to mitochondrial membranes and impede essential transport pores, diminishing mitochondrial energy output and increasing cellular stress.
Experimental data in mice indicate that inactive GRK2 also promotes amyloid-beta production. Amyloid-beta, in turn, imposes additional stress on neurons and promotes further GRK2 inactivation, creating a vicious cycle that accelerates neuronal damage and disease progression.
Compound 10 breaks the cycle and shows anti‑aging effects
To interrupt this cycle, the team synthesized and screened a series of small molecules. Compound 10 emerged as a lead candidate that prevents GRK2 from aggregating. In cultured neurons and aged mouse models, Compound 10 restored mitochondrial function, reduced amyloid-beta deposition, preserved neuronal integrity, and improved survival.
Notably, treated mice also demonstrated improvements beyond the brain: cardiac function improved and several systemic signs consistent with slower biological aging were observed, such as reduced greying of fur in older animals.
Why the project spanned nearly 20 years
Alzheimer’s research demands long-term experiments because the disease is age-related. Validating effects in older animals (approximately 18–24 months for mice) means each experimental cycle can take one to two years, so sequential, interlocking studies naturally extend the timeline. The research team has completed the foundational studies and filed a patent for Compound 10, and ETH Zurich is now seeking industry partners to advance drug development.
“Alzheimer’s is a complex disease,” says Professor Quitterer. “Existing medications offer limited delay of progression. Identifying GRK2 as a new target and discovering an agent that operates by preventing GRK2 aggregation introduces a distinct mechanism that could be combined with other treatments to improve patient outcomes.”
Key Questions Answered:
A: Through metabolic changes in aging and disease. GRK2 becomes phosphorylated and inactivated, forming aggregates that coat mitochondrial membranes, block pore function, and deprive neurons of the energy they need to survive.
A: Inactive, aggregated GRK2 drives increased amyloid-beta production. Amyloid-beta stresses neurons and promotes further GRK2 inactivation and aggregation, creating a self-sustaining loop that accelerates degeneration.
A: Because faithfully modeling age-related neurodegeneration requires older animals and long experimental timelines. Each study cycle in aged mice can take up to two years, so building a validated, sequential research program is time-consuming.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full for accuracy.
- Additional explanatory context was added by the editorial staff.
About this Alzheimer’s and neuropharmacology research news
Author: Marianne Lucien
Source: ETH Zurich
Contact: Marianne Lucien – ETH Zurich
Image credit: Neuroscience News
Original Research (open access): “Analysis of GRK2 aggregation in the pathology of Alzheimer disease in animal models” by Joshua Abd Alla, Alexander Perhal, Xuebin Fu, Andreas Langer, Yasser el Faramawy, and Ursula Quitterer. DOI: 10.1016/j.xcrm.2026.102707. Published in Cell Reports Medicine.
Abstract
Analysis of GRK2 aggregation in the pathology of Alzheimer disease in animal models
G protein–coupled receptor kinase 2 (GRK2) plays essential roles in cell growth and survival. Investigating GRK2 in Alzheimer’s disease, researchers found increased aggregated serine-670–phosphorylated GRK2 (phospho‑S670‑GRK2) in brains of Alzheimer’s mice and patients with dementia likely due to Alzheimer’s. Aggregation of phospho‑S670‑GRK2 is induced by beta‑amyloid and tau pathology and triggers aggregation of TOMM6, promotes mitochondrial dysfunction, and enhances beta‑amyloid accumulation. Transgenic expression of inactive GRK2 variants or GRK‑inhibitory peptides established that GRK2 inactivation drives neuropathological features. Restoring TOMM6 in neurons reduced plaque burden but increased soluble beta‑amyloid and mortality, whereas restoring monomeric GRK2 and promoting proteasomal degradation of phospho‑S670‑GRK2 with small molecules counteracted Alzheimer‑like pathology, prevented neuronal loss, and improved survival. These results suggest that targeting pathological GRK2 aggregation can slow age‑associated neurodegeneration.